Hip arthritis in the TNF-Blockade era: an unresolved issue? by Scott, C et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Hip arthritis in the TNF-Blockade era: an unresolved issue?
C Scott*, C Wouters and P Moens
Address: University Hospital Leuven, Leuven, Belgium
* Corresponding author    
Background
Hip involvement is a major cause of morbidity in patients
with JIA. TNF-antagonists have improved the control of
JIA.
Methods
We report on the evolution of hip arthritis in a series of 15
JIA (7 m/8 f; 9 sJIA, 4 pJIA, 2 oeJIA) patients treated with
TNF-antagonists add-on MTX. Clinical disease activity,
medication, hip x ray and MRI images were recorded.
Results
Median disease duration at start of TNF blockade was 51
months (14 – 108). Follow-up under TNF-blockade was
42 months (11–107).
Ten patients had hip involvement at start. Eight (7 sJIA, 1
eoJIA) showed progressive hip disease (PHD) during TNF
blockade.
In patients with PHD active joint count decreased from 10
to 2.5. Systemic inflammation decreased (ESR 48.5 to
22.5). Steroid dose decreased from 0.315 mg/kg/d at start
to 0.155 mg/kg/d. In 4, steroid tapering was impossible
necessitating alternative therapy.
Hip imaging in 8 PHD children showed cartilage destruc-
tion, erosions and sclerosis (7) osteonecrosis of the femo-
ral head (6), AVN (1), extensive osteophyte formation
(1).
Discussion
In this cohort of 15 patients treated with TNF blockade, 8
patients had progressive hip disease despite better control
of articular and systemic inflammation in the majority of
them. Our findings suggest that the risk of progressive hip
disease and damage may not be sufficiently abrogated by
TNF blockade. Hip disease may progress despite a good
general response and requires special vigilance especially
in patients who do not show an optimal response to TNF
antagonism.
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